📄 What This Document Is

This is NovaBridge Biosciences' Form 20-F, their annual report for the year ended December 31, 2025. It’s filed with the U.S. SEC and is required because their shares (as American Depositary Shares, or ADSs) trade on the Nasdaq. Think of it as the company’s comprehensive yearly "check-up" and update for investors.

👉 In simple terms, it’s the official, detailed report that tells shareholders and the market exactly where the company stands after a year of major change.

🏢 The Company's Big Pivot

NovaBridge Biosciences (ticker: NBP) is a clinical-stage biopharmaceutical company that has just undergone a massive transformation.

👉 In simple terms, they used to be a China-based biotech called I-Mab. In April 2024, they completed a huge shift: they divested (sold off) their entire Greater China business and assets. Now, they are a U.S.-incorporated company (based in Rockville, MD) with a sharp focus on developing cancer drugs (precision immuno-oncology) and eye disease treatments (ophthalmology).

They are essentially a "new" company built on a portfolio of drug candidates for which they own rights outside of Greater China.

💰 Financial Snapshot: A Story of Losses and Cash

The numbers tell the story of a research-heavy company that is not yet profitable.

Net Losses: The company is burning cash to fund development.
- 2025: $88.3 million net loss
- 2024: $22.2 million net loss (lower due to the divestiture)
- 2023: $207.7 million net loss
Cash is King: Their survival depends on their cash reserves.
- Cash Position (Dec 31, 2025): $210.8 million in cash, equivalents, and short-term investments.
- Cash Runway: Management believes this is enough to fund operations into the fourth quarter of 2028.
Recent Capital Raise: In August 2025, they raised $61.2 million (net) by selling new shares. This was crucial to bolster their finances after the China exit.

🔬 The Pipeline: What They're Building

With the China business gone, NovaBridge's future rests on its remaining "Global portfolio." Here are the key assets:

Givastomig: A bispecific antibody in clinical trials. It's their most advanced asset, with trials ongoing in the U.S.
VIS-101: Another clinical-stage candidate.
Ragistomig & Uliledlimab: Two more drug candidates with FDA Investigational New Drug (IND) applications open.

The company also has partnerships, like a licensing deal with AbbVie for certain assets, which can provide non-dilutive funding through milestones and royalties.

⚠️ Major Risks & Challenges

The filing lays out significant hurdles NovaBridge must overcome.

Clinical Development Risk: This is the core risk. Drug development is expensive, takes years, and most candidates fail. A single failed clinical trial could be devastating.
Regulatory Risk: Getting a drug approved by the FDA and other agencies is a long, uncertain process. They could face unexpected delays or rejections.
Need for Future Funding: Despite their cash runway, they will need to raise more money in the future to fund late-stage trials and commercialization. This could dilute existing shareholders.
Operational Risks: They disclosed material weaknesses in their internal IT controls. While they say it didn't cause financial errors, it's a red flag they are working to fix.
China Regulatory Risk: Even though they've left China, they could still face scrutiny from Chinese regulators (like the CSRC) over past or future offshore financings, which could cause delays or penalties.

🔮 What's Next: The Road Ahead

The company's strategy post-divestiture is clear:

Advance the Pipeline: Use their cash to fund clinical trials for lead candidates like givastomig.
Execute the New Model: They plan to grow through strategic partnerships and acquiring new drug assets.
Stay Lean: They underwent a 27% workforce reduction in January 2025 (a "Realignment Plan") to cut costs and focus resources.
Seek More Capital: They will likely need to return to the market for more funding as they progress.

🌍 Big Picture: Strengths vs. Risks

👍 Strengths:

Clean Slate: The China divestiture simplified their business and removed major operational complexity.
Focused Pipeline: They are now solely focused on high-potential areas in oncology and ophthalmology.
Cash Runway: They have a multi-year financial buffer to execute their plan.
Partnership Experience: Their deal with AbbVie shows they can attract big pharma partners.

⚠️ Risks:

Binary Outcomes: As a clinical-stage company, its value will swing dramatically on single trial results.
Cash Consumption: They are not profitable and will need more investors' money.
Execution Risk: The new management team must successfully build a U.S.-focused biotech from the ground up.
Market Dependency: Their fate is tied to the volatile biotech funding environment.

🧠 The Analogy

NovaBridge is like a ship that has jettisoned its heavy, leaking cargo (the China business) in the middle of the ocean. It’s now lighter and can steer a new course, but it’s in open water with a finite amount of fuel (cash), sailing toward a distant island (drug approval). Every storm (failed trial) or calm spell (funding drought) could determine whether it makes it to shore.

🧩 Final Takeaway

NovaBridge Biosciences is a high-stakes bet on a pipeline of new cancer and eye drugs. The company has successfully executed a radical pivot away from China, giving it a cleaner story and a focused mission. Its success now hinges entirely on whether it can use its remaining cash to generate positive clinical data that attracts partners or launches it toward profitability. Investors are betting on the science, not the past.

Company Contact: Kyler Lei, Chief Financial Officer 2440 Research Boulevard, Suite 400, Rockville, MD 20850, United States Phone: (240) 745-6330

NovaBridge Biosciences — 20-F Filing